Payne H - Search Results

1

Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey.

Lorente D, Ravi P, Mehra N, Pezaro C, Omlin A, Gilman A, Miranda M, Rescigno P, Kolinsky M, Porta N, Bianchini D, Tunariu N, Perez R, Mateo J, Payne H, Terstappen L, IJzerman M, Hall E, de Bono J. Lorente D, et al. Among authors: payne h. Eur Urol Focus. 2018 Mar;4(2):235-244. doi: 10.1016/j.euf.2016.09.005. Epub 2016 Oct 10. Eur Urol Focus. 2018. PMID: 28753792 Free article.

2

Tumour markers for managing men who present with metastatic prostate cancer and serum prostate-specific antigen levels of <10 ng/mL.

Birtle AJ, Freeman A, Masters JR, Payne HA, Harland SJ; BAUS Section of Oncology Cancer Registry. Birtle AJ, et al. BJU Int. 2005 Aug;96(3):303-7. doi: 10.1111/j.1464-410X.2005.05619.x. BJU Int. 2005. PMID: 16042718

3

Transdermal oestrogen therapy as a second-line hormonal intervention in prostate cancer: a bad experience.

Kandola S, Anyamene N, Payne H, Harland S. Kandola S, et al. Among authors: payne h. BJU Int. 2007 Jan;99(1):53-5. doi: 10.1111/j.1464-410X.2007.06543.x. BJU Int. 2007. PMID: 17227492

4

Management of locally advanced prostate cancer.

Payne H. Payne H. Asian J Androl. 2009 Jan;11(1):81-7. doi: 10.1038/aja.2008.9. Epub 2008 Dec 1. Asian J Androl. 2009. PMID: 19050683 Free PMC article. Review.

5

Prostate-specific antigen: an evolving role in diagnosis, monitoring, and treatment evaluation in prostate cancer.

Payne H, Cornford P. Payne H, et al. Urol Oncol. 2011 Nov-Dec;29(6):593-601. doi: 10.1016/j.urolonc.2009.11.003. Epub 2010 Jan 8. Urol Oncol. 2011. PMID: 20060331 Review.

6

Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer.

Trump DL, Payne H, Miller K, de Bono JS, Stephenson J 3rd, Burris HA 3rd, Nathan F, Taboada M, Morris T, Hubner A. Trump DL, et al. Among authors: payne h. Prostate. 2011 Sep;71(12):1264-75. doi: 10.1002/pros.21342. Epub 2011 Jan 26. Prostate. 2011. PMID: 21271613 Clinical Trial.

7

Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities.

Payne H, Bahl A, Mason M, Troup J, De Bono J. Payne H, et al. BJU Int. 2012 Sep;110(5):658-67. doi: 10.1111/j.1464-410X.2011.10886.x. Epub 2012 Mar 19. BJU Int. 2012. PMID: 22429837

8

Evolution of the treatment paradigm for patients with metastatic castration-resistant prostate cancer.

Malik Z, Payne H, Ansari J, Chowdhury S, Butt M, Birtle A, Sundar S, Eswar CV, Hughes S, Bahl A. Malik Z, et al. Among authors: payne h. Adv Ther. 2013 Dec;30(12):1041-66. doi: 10.1007/s12325-013-0070-z. Epub 2013 Nov 26. Adv Ther. 2013. PMID: 24276853 Review.

9

Is there an antiandrogen withdrawal syndrome with enzalutamide?

Rodriguez-Vida A, Bianchini D, Van Hemelrijck M, Hughes S, Malik Z, Powles T, Bahl A, Rudman S, Payne H, de Bono J, Chowdhury S. Rodriguez-Vida A, et al. Among authors: payne h. BJU Int. 2015 Mar;115(3):373-80. doi: 10.1111/bju.12826. Epub 2014 Oct 24. BJU Int. 2015. PMID: 24906049

10

Primary radical therapy selection in high-risk non-metastatic prostate cancer.

Gnanapragasam VJ, Payne H, Syndikus I, Kynaston H, Johnstone T. Gnanapragasam VJ, et al. Among authors: payne h. Clin Oncol (R Coll Radiol). 2015 Mar;27(3):136-44. doi: 10.1016/j.clon.2014.11.004. Epub 2014 Nov 28. Clin Oncol (R Coll Radiol). 2015. PMID: 25441052 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

417 results

Search Page

Filters